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Abstract
Background: The identification of clinically meaningful and predictive models of disposition kinetics for cancer therapeutics
is an ongoing pursuit in drug development. In particular, the growing interest in preclinical evaluation of anti-angiogenic
agents alone or in combination with other drugs requires a complete understanding of the associated physiological
consequences.
Methodology/Principal Findings: Technescan
TM PYP
TM, a clinically utilized radiopharmaceutical, was used to measure
tissue vascular volumes in beige nude mice that were naı ¨ve or administered a single intravenous bolus dose of a murine
anti-vascular endothelial growth factor (anti-VEGF) antibody (10 mg/kg) 24 h prior to assay. Anti-VEGF had no significant
effect (p.0.05) on the fractional vascular volumes of any tissues studied; these findings were further supported by single
photon emission computed tomographic imaging. In addition, apart from a borderline significant increase (p=0.048) in
mean hepatic blood flow, no significant anti-VEGF-induced differences were observed (p.0.05) in two additional
physiological parameters, interstitial fluid volume and the organ blood flow rate, measured using indium-111-pentetate and
rubidium-86 chloride, respectively. Areas under the concentration-time curves generated by a physiologically-based
pharmacokinetic model changed substantially (.25%) in several tissues when model parameters describing compartmental
volumes and blood flow rates were switched from literature to our experimentally derived values. However, negligible
changes in predicted tissue exposure were observed when comparing simulations based on parameters measured in naı ¨ve
versus anti-VEGF-administered mice.
Conclusions/Significance: These observations may foster an enhanced understanding of anti-VEGF effects in murine tissues
and, in particular, may be useful in modeling antibody uptake alone or in combination with anti-VEGF.
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Introduction
The absence of many physiological processes in vitro and
interspecies differences in vivo can confound direct comparisons of
in vitro, preclinical, and clinical data [1,2]. A vast array of
physiological data for humans and laboratory species is available
in the literature [3,4,5,6]; however, it should be utilized with an
understanding of its limitations. Significant physiological variabil-
ity across species, age, breed, disease status, drug treatment, and
time of day [7] motivates direct measurement of relevant
physiological properties or processes whenever possible [8].
The measurable effects of anti-vascular endothelial growth
factor (anti-VEGF) therapy on tumors in preclinical and clinical
settings include reductions in vascular density, vascular volume,
vessel permeability, and/or blood flow [9]; however, changes have
also been reported for small molecule VEGF inhibitors in non-
malignant tissues [10]. For instance, inhibition of VEGF in mice
using non-antibody-based anti-angiogenic agents induced distinct
physiological changes, including reduced cardiac output, changes
in blood glucose regulation, reduction of endothelial cell
fenestrations, and significant capillary regression in several tissues
[10]. Several VEGF inhibitors have yielded measureable, although
generally manageable, adverse effects in the clinical oncology
setting [11], thus encouraging further studies into the underlying
mechanisms behind the observed biological changes.
Preclinical studies evaluating the effects of anti-angiogenic
antibodies on all aspects of tissue physiology may have important
implications, especially given the increased clinical interest in
antibodies against angiogenic targets [9]. The present study
investigates the impact of a cross-species anti-VEGF antibody
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volumes (Vi), and regional rates of blood flow (Q) for selected
tissues in nude mice (Figure 1).
Physiologically-based pharmacokinetic (PBPK) modeling can aid
in understanding mechanisms of tissue uptake and can predict, by
means of inter-species scaling, tissue concentrations of therapeutic
antibodies in humans based on preclinical PK data of molecules
currently in development [13]. The success of PBPK modeling,
however, is dependent on parameter values that accurately reflect
in vivo tissue physiological conditions. Importantly, a sensitivity
analysis of a previously reported PBPK model implicated Vv and Vi
as two of the most influential parameters on antibody concentra-
tion in tissues, particularly at early time points [5]. In addition,
preclinical and clinical magnetic resonance imaging studies have
demonstrated changes in parameters describing Vv and Q and/or
vessel permeability in tumors following anti-VEGF treatment [9].
In this context, tissue uptake of a generic IgG was predicted
by physiologically-based pharmacokinetic (PBPK) modeling
(Figure 2) using Vv, Vi and Q values obtained from the literature,
measured in naı ¨ve mice, or measured in mice receiving anti-VEGF;
predicted uptake values were compared to experimental uptake
data for a model antibody (trastuzumab) in nude mice.
Results
Vascular volume
Successful RBC labeling with
99mTc was evident due to
observed association of the vast majority of radioactivity with
the RBC pellet fraction for both naı ¨ve and B20-4.1-administered
mice (Figure 3). For the direct RBC labeling method, the mean
%ID/g values for the naı ¨ve and B20-4.1-administered mice,
respectively, were 0.7960.14 vs. 0.7560.11 in plasma, 39.6614.2
vs. 49.764.4 in whole blood, and 77.1627.3 vs. 97.369.3 in the
RBC pellet. To ensure that the anti-angiogenic effects did not
interfere with the measurement, a refined indirect method for
measuring Vv [2] allowed red blood cell (RBC) labeling to be
performed in a separate cohort of naı ¨ve (i.e. receiving no anti-
VEGF) mice. For the indirect method, the mean %ID/g values for
the naı ¨ve and B20-4.1-administered mice, respectively, were
0.6360.19 vs. 0.5760.13 in plasma, 55.162.5 vs. 53.363.6 in
whole blood, and 98.366.2 vs. 96.867.5 in the RBC pellet.
Mean values with standard deviations were calculated for direct
and indirect Vv data from both dose groups and compared to
literature values (Table 1). Using the direct method, no
differences in Vv for brain and muscle were observed when
comparing naı ¨ve and B20-4.1-administered mice. Differences,
expressed as [(Vv,B20-4.12Vv,naı ¨ve)/Vv, naı ¨ve]6100%, were noted in
spleen (5% increase), liver (11% decrease), kidney (27% decrease),
intestine (22% decrease), heart (9% decrease), lung (11% decrease),
and fat (7% increase). None of these differences were statistically
significant by unpaired t-test (p.0.05). Using the indirect method,
no differences in Vv were observed between naı ¨ve and B20-4.1-
administered mice for brain, muscle, and fat. Percent differences
for remaining tissues, expressed as [(Vv,B20-4.12Vv,naı ¨ve)/Vv, naı ¨ve]
6100%, were as follows: spleen (9% increase), liver (1% decrease),
kidney (7% decrease), intestine (30% increase), heart (27%
increase), and lung (21% decrease). None of these differences
was statistically significant by unpaired t-test (p.0.05).
Excellent agreement between indirectly measured (in naı ¨ve
mice) and literature Vv values, respectively, was observed for brain
Figure 1. Conceptual illustration of techniques used to measure physiological parameters relevant to antibody uptake in tissues.
The tissue is divided into vascular, interstitial, and cellular compartments (depicted in red, green, and blue, respectively). The blood space (Vv) may be
measured using
99mTc-labeled red blood cells (RBC), while the extracellular (i.e. Vv+Vi) space is measured by infusion of
111In-DTPA. The rate of blood
flow (Q) to the tissue may be measured as the proportion of a bolus dose of
86RbCl that enters the tissue in a brief time interval. The antibody’s
receptor, if present, may be expressed on the cell surface, exposed to the interstitial fluid. An antibody in circulation may extravasate from blood into
interstitial space at a rate (k), where it may encounter a number (Bo) of receptors for which it has binding affinity (Ka). The antibody may also return to
circulation via lymphatic flow (L).
doi:10.1371/journal.pone.0017874.g001
Anti-VEGF Effects on Murine Physiology
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17874(1162 vs. 9.4 mL/g) and spleen (121629 vs. 100 mL/g) (Table 1).
In contrast, the direct method yielded Vv values more closely
matching the corresponding literature values for intestine (22612
vs. 29 mL/g) and muscle (1566 vs. 18.9 mL/g).
SPECT-CT imaging
The whole-body distributions of
99mTc-labeled RBCs for the
two dose groups were visually assessed by single photon emission
computed tomography/X ray computed tomography (SPECT-
CT) imaging. Both the sagittal planar images (left) and the three-
dimensional volume rendered images (right) revealed similar blood
distributions for both naı ¨ve and B20-4.1-administered mice
(Figure 4). Slight splenic uptake was evident in the SPECT-CT
volume rendered images of mice in both dose groups. It should be
noted that the magnitude of bladder uptake may be affected by
differences in the time between injection and the start of SPECT
data acquisition (98 min for naı ¨ve, 138 min for B20-4.1-admin-
istered mouse); in contrast, the mice that were used to generate the
data in Figure 3 were promptly sacrificed at 1 h post-injection of
99mTc.
Interstitial volume
From the calculated interstitial fluid volume data in naı ¨ve and
B20-4.1-administered mice, mean Vi values were obtained and
compared to literature values (Table 2). It should be noted that
because the calculation of Vi requires knowledge of Vv,i t s
accuracy is dependent on both the RBC labeling and indium-
111 diethylenetriamine-N,N,N9,N9,N0-pentaacetic acid (
111In-
DTPA; i.e.,
111In-pentetate) infusion studies. Mean Vi values
for B20-4.1-administered relative to naı ¨ve mice, expressed as
[(Vi,B20-4.12Vi,naı ¨ve)/Vi, naı ¨ve]6100%, were as follows: brain (80%
increase), spleen (8% decrease), liver (20% increase), intestine
(25% increase), heart (5% increase), lungs (50% increase),
muscle (32% increase), and fat (11% decrease). With the
exception of brain, none of these differences is statistically
significant by unpaired t-test (p.0.05). For brain, the difference
exhibits a borderline statistical significance by unpaired t-test
(p=0.05).
Agreement between measured (in naı ¨ve mice) and literature Vi
values, respectively, was observed for intestine (121662 vs.
174 mL/g), heart (158667 vs. 143 mL/g), muscle (114619 vs.
130 mL/g), and fat (3466259 vs. 490 mL/g) (Table 2). The Vi
value for brain in mice (2065 mL/g) does not agree with the
literature value in mice (170–190 mL/g) [14] due to an inability of
the radiometal-chelate complex to cross the blood-brain barrier
(Table 2). Similarly, the Vi value for kidneys in naı ¨ve mice
(22026462 mL/g) is also physiologically irrelevant due to renal
clearance of the extracellular probe,
111In-DTPA (Table 2).
Figure 2. Diagram of physiologically-based pharmacokinetic (PBPK) model to predict antibody uptake in tissues. Shown is a typical
tissue sub-model component of the PBPK model [13] used to assess the influence of parameter variability among literature and measured Vv, Vi and Q
values on tissue uptake of an IgG (expressed as AUC0–7). Antibody enters tissue from the central plasma compartment via arterial blood flow where it
continues to the lungs via venous blood flow or returns directly to the central plasma compartment through the lymphatic system subsequent to
extravasation into interstitial space. The AUC0–7 values listed in Table 4 are the sum of AUCs of absolute antibody amount vs. time in the two tissue
compartments (x2 andx3) multiplied by 100% and divided by the product of the total injected dose and mass of tissue, yielding AUC in units of %ID/g6
time. Note that the muscle sub-model includes extra compartments, included in the AUC0–7 calculation, that describe FcRn mediated recycling and
degradation of antibody.
doi:10.1371/journal.pone.0017874.g002
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From the calculated blood flow data in naı ¨ve and B20-4.1-
administered mice, mean Q values (mL/g/min) were obtained
and compared to literature values (Table 3). Percent differences
in mean Q values, expressed as [(Q,B20-4.12Q,naı ¨ve)/Q,n a ı ¨ve]
6100%, were as follows: liver (27% increase), kidneys (19%
increase), heart (17% increase), muscle (6% increase), fat (18%
increase), spleen (9% decrease), intestine (9% decrease), and
unchanged in lungs. With the exception of liver, none of these
differences is statistically significant by unpaired t-test (p.0.05).
For liver, by conventional criteria, the difference is considered
to be borderline statistically significant by unpaired t-test
(p=0.048).
Agreement between measured (in naı ¨ve mice) and literature Q
values, respectively, was observed for intestine (3806136 vs.
474 mL/g/min) and muscle (186647 vs. 184 mL/g/min) (Table 3)
[5]. The Q value for brain in naı ¨ve mice (1261 mL/g/min) does
not agree with the literature value (850 mL/g/min) [3,15] due to
an inability of the radiometal cation,
86Rb
+, to cross the blood-
brain barrier.
PBPK simulations
Listed in Table 4 are the simulated AUC0–7 values for blood
and various tissues using a PBPK model parameterized with both
literature and measured values of Vv, Vi, and Q, with the exception
of kidney, for which literature values of Vi, were always used. The
substitution of measured physiological parameter values in naı ¨ve
mice resulted in changes in AUC0–7 values, expressed as [(AUC0–7,
measured2AUC0–7, literature)/AUC0–7, literature]6100%, as follows: 35%
increase in lungs, 15% increase in spleen, 13% increase in blood
and bone, 48% decrease in liver, 46% decrease in intestine, 28%
decrease in muscle, 5% decrease in kidneys, and 1% increase in
heart. Note that no experimental bone measurements were made
in this study. Literature values were used for this tissue in all cases,
and changes in bone reflect altered plasma PK profiles.
Model-predicted AUC values may also be compared to
experimentally measured values obtained from tissue distribution
data (Table 4). The use of experimentally measured Vv, Vi, and Q
values in naı ¨ve mice produced simulations that more closely
matched measured AUC0–7 values in blood, spleen, and muscle,
but not in liver, kidneys, and lungs when compared to simulations
based on literature values. Specifically, the use of literature and
measured parameter values, respectively, gave differences, ex-
pressed as [(AUC0–7, model-predicted2AUC0–7, experimental)/AUC0–7,
experimental]6100%, as follows: 44% higher vs. 4% higher in muscle,
11% higher vs. 50% higher in lungs, 45% lower vs. 37% lower in
spleen, 32% lower vs. 24% lower in blood, 28% lower vs. 28%
lower in heart, 13% lower vs. 55% lower in liver, and 14% lower
vs. 18% lower in kidneys.
Model-predicted AUC values obtained using experimentally
measured values in naı ¨ve and anti-VEGF-administered mice were
very similar in blood and most tissues (Table 4). The use of
measured parameter values in naı ¨ve and B20-4.1-administered
Figure 3. Measurement of technetium-99m incorporation in
fractionated red blood cells. (A) Technetium-99m radioactivity,
expressed as percentage of injected
99mTc dose per gram (%ID/g), in
fractionated blood for mice (n=5) whose red blood cells were labeled
by the direct method. Mice were either naı ¨ve or administered a single
intravenous bolus dose (10 mg/kg) of the cross-species anti-VEGF
antibody, B20-4.1, 24 h prior to assay. (B) Technetium-99m radioactivity,
expressed as %ID/g, in fractionated blood from mice (n=5) whose red
blood cells were labeled by the indirect method. All donor mice were
naı ¨ve; recipient mice were naı ¨ve or received a single intravenous bolus
dose (10 mg/kg) of the cross-species anti-VEGF antibody, B20-4.1, 24 h
prior to assay.
doi:10.1371/journal.pone.0017874.g003
Table 1. Measured vascular volumes (Vv) in naı ¨ve and anti-
VEGF-administered mice.
Tissue Vv (Lit.) Vv, Measured (Naı ¨ve)h Vv, Measured (+ B20)
Direct Indirect Direct Indirect
brain 9.4
a, d 11621 1 621 1 611 1 61
spleen 100
b, e 149621 121629 156691 3 3 662
liver 100
b, e 193634 42681 7 3 624 4168
kidney 100
b, e 4286117 77673 1 1 631 72614
intestine 29
b, f 22612 8621 7 631 0 64
heart 52.6
b, f 45653 0 674 1 611 38610
lung 100
b, e 216646 2356111 192675 186626
muscle 18.9
b, f 15669 621 5 699 65
fat 20
c, g 61630 14646 5 639 1467
Note: Literature (Lit.) values are listed for comparison. Nude mice (n=5) were
naı ¨ve or administered a single, intravenous bolus dose (10 mg/kg) of the cross-
species anti-VEGF antibody [12], B20-4.1, 24 h prior to assay. All values are
reported in mL/g. Values of Vv were measured using both direct and indirect
RBC labeling methods [2]. Note that the assay method can greatly influence
measured Vv, especially in probe clearance organs.
a[39].
b[5].
c[3].
dMeasured using
3H-inulin.
eFor well-perfused organs 10% vascular space is assumed [5].
fEstimated from experimental IgG data at early time points [5].
gEstimated from human data.
hData reproduced with permissions [2].
doi:10.1371/journal.pone.0017874.t001
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PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17874Figure 4. Noninvasive SPECT-CT imaging of blood pool in naı ¨ve and anti-VEGF-administered mice. Representative SPECT-CT blood pool
images (n=1) obtained at 98–138 min post injection in mice that were either naı ¨ve (A–B) or administered (C–D) a single intravenous bolus dose
(10 mg/kg) of the cross-species anti-VEGF antibody, B20-4.1, approximately 24 h prior to image acquisition. Red blood cell labeling was performed by
the indirect method. The false-colored SPECT images in arbitrary uptake units are fused onto the X-ray CT images. Both a sagittal planar image along
the spine (A, C) and a corresponding three-dimensional volume rendered image (B, D) are shown for each reconstructed SPECT-CT fusion dataset.
Mostly blood pool and bladder uptake are evident in the sagittal slices, while the spleen can also be clearly delineated in the right-hand side of the
3D images, just below the ribcage. The locations of visible uptake in heart (h), spleen (sp), and bladder (bl) are indicated in the volume rendering
images.
doi:10.1371/journal.pone.0017874.g004
Table 2. Measured interstitial volumes (Vi) in naı ¨ve and anti-
VEGF-administered mice.
Tissue Vi (Literature) Vi, Measured (Naı ¨ve) Vi, Measured (+ B20)
brain 170–190
a, d 2065
e 36615
e
spleen 200
b 25610 23632
liver 200
b, g 90615 108623
kidney 339
b, g 22026462
f 25886506
f
intestine 174
b, h 121662 151696
heart 143
b, h 158667 166641
lung 300
b, g 173671 2596111
muscle 130
b, i 1146119 150647
fat 490
c, i 3466259 3086121
Note: Literature values are listed for comparison. Nude mice (n=5) were naive
or administered a single, intravenous bolus dose (10 mg/kg) of the cross-
species anti-VEGF antibody [12], B20-4.1, 24 h prior to assay. All values are
reported in mL/g. Note that the assay method can greatly influence measured Vi
values, especially in probe clearance organs.
a[14].
b[5].
c[23].
dTetramethylammonium (TMA
+) method; corrected for a reported 9.4 mL/g
blood volume [14].
eReflects inability of
111In-DTPA to cross the blood-brain barrier.
fNon-physiologically relevant measurement due to renal clearance of
111In-
DTPA.
gExtrapolated from rat; sodium (extracellular marker) content determined in a
flame photometer [22].
hEstimated on the basis of values for similar tissues [5].
iExtrapolated from rat;
51Cr-EDTA method [5,23].
doi:10.1371/journal.pone.0017874.t002
Table 3. Volume velocities of regional blood flow (Q) in naı ¨ve
and anti-VEGF-administered mice.
Tissue Q, Literature Q, Measured (Naı ¨ve) Q, Measured (+ B20)
brain 850
a, e 1261
d 1261
d
spleen 909
b, f 1696105 153671
liver 2103
b, f 158620* 200635*
kidney 4881
b, g 11726419 13906537
intestine 474
b, f 3806136 3466105
heart 3828
b, f 877663 10266236
lung 350
a, h 5386150 5376262
muscle 184
b, i 186647 198659
fat 190
c, j 120637 142634
Note: Literature values are listed for comparison. Nude mice (n=5) were naı ¨ve
or administered a single, intravenous bolus dose (10 mg/kg) of the cross-
species anti-VEGF antibody [12], B20-4.1, 24 h prior to assay. All values are
reported in mL/g/min. Note that the assay method can greatly influence
measured values of Q, especially in probe clearance organs.
*p,0.05 by unpaired t-test.
a[3].
b[5].
c[40].
dReflects inability of probe to cross blood-brain barrier.
e85Sr-labeled microspheres [15].
fOrigin of measurement not specified in literature.
gExtrapolated from inulin clearance rates in rat kidney [41].
hBronchial flow.
iMeasured experimentally by Rb uptake method.
jRat data; method not specified [40].
doi:10.1371/journal.pone.0017874.t003
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as [(AUC0–7, naı ¨ve2AUC0–7, B20-4.1)/AUC0–7, naı ¨ve]6100%: 25%
higher in intestine, 10% higher in heart and spleen, 3% higher in
liver, 1% higher in lungs, 0.1% higher in blood and bone, 4%
lower in kidneys, and 0.1% lower in muscle.
Discussion
No significant change in three measured physiological param-
eters was observed for most healthy murine tissues, despite the fact
that the chosen dosage of B20-4.1 was based on previously
reported xenograft growth inhibition activity [16] that should
result in a minimum trough concentration at steady state of
,30 mg/mL, similar to that achieved in .90% of bevacizumab
patients [17]. Furthermore, selection of the 24 h time point was
guided by reported statistically significant reductions in vascular
density of human xenografts in mice at 24 h following anti-VEGF
administration [9]. The lack of observed changes in physiology
reported herein may reflect lower murine VEGF levels in healthy
tissues relative to tumors in mice. Indeed, an analogous scenario
has been exploited in clinical imaging of VEGF-expressing tumors
with radiolabeled bevacizumab, where metastatic lesions were
clearly delineated [18]. However, these findings do not preclude
possible changes in additional physiological parameters such as
vascular permeability to immunoglobulins; additional studies in
this context are ongoing.
The blood volume measurement data indicated that the %ID/g
values for whole blood were roughly half of those for the RBC
pellet by either the direct or indirect labeling method, consistent
with an average hematocrit value of 45% in mice [4]. Although
the differences in RBC labeling efficiency between naı ¨ve and B20-
4.1-administered mice were not statistically significant, the mean
values in blood and RBC pellet were higher for the B20-4.1-
administered mice, possibly due to anti-VEGF-mediated decrease
in nitric oxide (NO) synthesis and concomitant vasoconstriction
that would prolong the exposure of RBCs to Sn
2+ and/or
99mTc
pertechnetate. These observations led to the development and
utilization of the indirect method to ensure that such effects were
not confounding the Vv results [2].
The overall similarity in distributions of radioactivity between
the two images (Figure 4) was consistent with the lack of
significant anti-VEGF effect on measured Vv values (Table 1).
Slight splenic uptake of
99mTc observed in SPECT-CT images was
observed, as expected, due the spleen’s physiological role in
sequestration of RBCs [19,20,21]. Furthermore, anti-VEGF
administration had no statistically significant effect on measured
Vi values (Table 2). Because calculation of Vi requires knowledge
of both vascular (
99mTc-RBC) and extracellular (
111In-DTPA)
spaces, statistical analysis of raw %ID/g
111In-DTPA data was
performed separately and showed no significant differences
between dose groups (data not shown).
Comparing the PBPK modeling results using literature and
measured parameter values demonstrates the importance of
obtaining accurate values for physiological parameters. While
the change in blood AUC is modest (13%) (Table 4), the impact
of using measured physiological values is potentially high when
simulating concentration-time curves within certain organs, with
changes in liver and intestine AUCs of approximately 50%.
Variability in AUC0–7 for liver is of particular significance when
modeling antibody biodistribution because of its role as a
clearance organ.
Although closer agreement between model predicted and
experimental AUC0–7 values was obtained using literature Vv, Vi,
and Q values in liver, kidneys, and lungs, the use of experimentally
determined parameter values gave superior results in blood,
muscle, and spleen (Table 4). Both methods demonstrated
roughly comparable performance in predicting AUC0–7 values in
heart. The excellent agreement between model predicted and
experimental values in muscle is of particular significance given
the inclusion of an FcRn submodel in the muscle sub-
compartment of the PBPK model [13]. This nonlinear two-
compartment submodel accounts for linear transfer of antibody
from organ vascular space to endosomes via nonspecific bulk fluid
uptake by endothelial cells, recycling of FcRn-bound antibody
back into plasma, and degradation of non-FcRn-bound antibody.
Difficulty in harvesting lungs without pooling of excess blood
during sacrifice may have influenced the calculated parameter
values for this tissue. In addition, clearance of physiological probes
may limit the validity of measurements. This effect was avoided for
the vascular volume measurement by use of an indirect RBC
labeling protocol to avoid contamination by non-RBC-associated
99mTc; however,
111In-DTPA and
86Rb are also subject to renal
clearance and, in the case of
111In-DTPA, possible transchelation
of radiometal into metalloproteins may encourage hepatic
accumulation. Due to the aforementioned complications, utiliza-
tion of nominal values for lungs, liver, and kidney may be superior
to the use of measured values.
The origin of values reported in the literature (Tables 1, 2, 3)
should be carefully considered, as many are in fact assumed
nominal values. For instance, a 10% vascular space is assumed for
well-perfused organs (e.g., kidney, lung, liver, and spleen), while,
other values are estimated based on experimental uptake data of
antibodies at early time points [5] (Table 1). In addition, multiple
methods exist for measuring physiological parameters. Three
distinct methods were used to obtain several Vi values that were
derived from a single reference in Table 2: analysis of sodium
content (in rat tissues) by flame photometry [22], estimation on the
basis of similar tissues [5], and use of the extracellular probe,
51Cr-
EDTA in rat tissues [5,23]. As expected, the best agreement is
found when similar methods are employed. For instance, the Vi
Table 4. Sensitivity of AUC0–7 for an antibody in mice to
changes in Vv, Vi and Q.
Tissue Model-Predicted AUC0–7 Values Experimental
a
Lit. Meas. (naı ¨ve) Meas. (+ B20) (naı ¨ve)
blood 82.5 93.0 93.1 122.2
liver 18.1 9.37 9.64 20.7
kidneys 18.7 17.8 17.1 21.8
spleen 15.4 17.7 19.4 28.1
lungs 36.7 49.5 50.2 33.1
heart 17.4 17.6 19.3 24.3
muscle 11.4 8.23 8.22 7.90
intestine 7.03 3.77 4.71 na
bone 7.58 8.55 8.56 na
Note: Comparison of model-predicted [13] and experimentally measured AUCs
[%ID/g day], up to 7 days post-injection, calculated for an intact antibody in
mice. All blood flow rates (Q), vascular (Vv) and interstitial (Vi) volumes were
simultaneously changed from literature to measured values (see Tables 1, 2,
3) for these simulations, with the exception of Vi for kidneys, for which literature
values were always used due to the effects of probe clearance. Measurement of
Vv was accomplished using a previously reported indirect RBC labeling method
[2].
aData for
125I-trastuzumab; reproduced with permissions [2].
doi:10.1371/journal.pone.0017874.t004
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the difference in species; this may be explained by similar chemical
properties of the radiometal-polyaminopolycarboxylate complexes
(i.e.
111In-DTPA and
51Cr-EDTA) used as extracellular markers.
Furthermore, the impressively good agreement between the
experimental (naı ¨ve) and literature Q values for muscle may be
explained by the fact that the identical method of rubidium uptake
was used to derive both values (Table 3). Interestingly, the Q
value for kidney reported in the same reference [5] was
extrapolated from inulin renal clearance rates, while the methods
used to derive many other values could not be found in the original
literature.
Of particular importance was the use of the indirect RBC
labeling technique in the determination of Vv. Application of the
traditional method of direct in vivo RBC labeling resulted in the
calculation of negative interstitial volume values for many tissues,
especially clearance organs (data not shown). This may be
explained by interference due to non-RBC-associated
99mTc,
leading to an incorrect assessment of vascular volume values. The
indirect method averts such difficulties through transfusion of
whole blood containing in vivo-purified
99mTc-labeled RBC from
donor mice into study mice.
Many clinically utilized drugs, including radiopharmaceuticals
for noninvasive imaging of physiological response to drug therapy
[24], may also be useful as probes in invasive preclinical studies.
For instance, convenient kit preparations for radiolabeling of red
blood cells can allow not only clinical blood pool imaging
[19,20,21,25] but also preclinical determination of vascular
volume in tumors and other tissues [7,26].
Limitations exist in measuring physiological quantities, espe-
cially in regards to organs involved in renal and hepatobiliary
clearance. Use of tabular physiological parameter data from a
single, well-referenced source is appealing due to convenience and
peer acceptance; in this context, an effort was made to select
literature values (Tables 1, 2, 3) from heavily cited sources that
are commonly used by PBPK modelers. However, for any single
physiological parameter, significant variability exists among values
reported by various sources; this discrepancy is often caused by
differences in experimental methodology. For many modeling and
simulation applications, rough estimates of physiological param-
eters may suffice; therefore, the use of such data is justified.
Nevertheless, those who utilize such information should be aware
of the experimental methods and/or estimations used to derive
measured physiological parameter values so that the limitations,
with respect to accuracy of PBPK model predictions, can be
known.
Nominal or in vitro physiological parameters are often necessary
in the use of PBPK models, which can lead to better
understanding and predictability of drug distribution into various
tissues [3,6,13,27]. PBPK models have been developed to predict
in vivo PK solely based upon in vitro and in silico absorption,
distribution, metabolism, and excretion (ADME) data together
with established physiological information that describes the
mammalian body [13]. Even relatively simple models can
significantly improve interpretation of uptake data by allocating
drug concentrations into distinct physiological compartments, such
as central plasma pool and peripheral tissue. Measurable tissue
physiological parameters such as fractional interstitial and blood
volumes can be used in a PBPK model [13,28,29,30] to facilitate
estimation of other parameters that yield additional insight into
drug PK beyond what is apparent from traditional tissue
distribution studies alone. For instance, correction of tissue
disposition data for the fraction of drug in the vascular
compartment is possible if the blood PK and tissue Vv are known;
this is particularly helpful for drugs having an interstitial or cellular
site of action (i.e. biophase).
In conclusion, responses to a single anti-VEGF treatment were
assessed by measuring three distinct physiological parameters in
nude mice. Administration of anti-VEGF had no statistically
significant effect on the fractional vascular volumes of any of the
tissues studied, and these findings were further supported by
SPECT imaging. In addition, with the exception of a marginally
significant increase in hepatic blood flow, no anti-VEGF-induced
differences were detected in interstitial fluid volume and organ
blood flow rates. Furthermore, PBPK model-predicted AUC0–7
values of an IgG were in better agreement with experimental
AUC0–7 values in blood, spleen, and muscle when using
experimentally measured compartmental volume and blood flow
values when compared to simulations based on literature values.
These observations may have important implications in the
mechanistic understanding and prediction of antibody uptake
alone or in combination with anti-VEGF therapy.
Materials and Methods
Radiopharmaceuticals
Rubidium-86 chloride (
86RbCl) was purchased from PerkinEl-
merH Life and Analytical Sciences, Inc. (Waltham, MA). Indium-
111-DTPA (i.e.
111In-pentetate) and technetium-99m (
99mTc)
pertechnetate were purchased from Covidien Radiopharmacy
(South San Francisco, CA). All three were diluted with sterile
normal saline prior to intravenous dosing. Technescan
TM PYP
TM
(i.e. stannous pyrophosphate +
99mTc) kits for preparation of
99mTc pyrophosphate injection were purchased from Covidien
Radiopharmacy (South San Francisco, CA) and used according to
label instructions for the in vivo method of blood pool imaging with
the appropriate human-to-mouse scaling.
Animal model
The protocol, housing, and anesthesia were approved (Protocol
numbers 09-2490 and 09-1245) by the Institutional Animal Care
and Use Committees of Genentech Laboratory Animal Resources,
in compliance with the Association for Assessment and Accred-
itation of Laboratory Animal Care regulations. Female beige nude
X-linked immunodeficient (XID) (bg.nu.xid Harlan Laboratories)
mice in a 6–8-week age range were used for all measurements.
Selected mice received B20-4.1, a cross-species anti-VEGF murine
antibody [12], which was intravenously administered in a 10 mg/
kg bolus dose 24 h prior to the Vv measurement; otherwise,
consistency in handling of all mice was exercised. Selection of the
B20-4.1 dose was based on previously reported xenograft growth
inhibition activity at weekly doses of 10 mg/kg in immunocom-
promised mice [16]. In addition, a pharmacokinetic model
simulation indicated that either a 5 mg/kg twice a week or
10 mg/kg weekly dosing regimen would result in a minimum
trough concentration at steady state of ,30 mg/mL, similar to that
achieved in .90% of bevacizumab patients [17]. Selection of the
24 h time point was guided by reported statistically significant
reductions in vascular density of human xenografts in mice at 24 h
following anti-VEGF administration [9].
Vascular volume
The intravascular spaces of murine tissues were measured using
both direct and indirect methods as previously described [2]. The
indirect method involved transfusion of radiolabeled blood from
donor mice into study (i.e. recipient) mice, where donor mice had
been subjected to
99mTc labeling of RBCs in vivo following
administration of stannous (Sn
2+) pyrophosphate [7,25]. Use of the
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TM PYP
TM kit is conceptually based on the
original method of Sands for in situ (i.e. in vivo) RBC labeling with
99mTc [26,31]. The previous administration of stannous pyro-
phosphate, a component of the reconstituted Technescan kit,
reduces
99mTc pertechnetate intracellularly so that it may bind to
the beta chain of hemoglobin [32].
Interstitial volume
The extracellular spaces of murine tissues were measured by
continuous infusion (via jugular cannulation) of the extracellular
marker,
111In pentetate [33,34]. A similar radiometal-polyamino-
polycarboxylate complex, chromium-51- ethylenediaminetetra-
acetic acid (
51Cr-EDTA), has been previously used by others in
a similar context [23]. Jugular cannulation surgeries were
performed on all mice 48 h prior to measurement to allow
recovery while maintaining a constant saline infusion at 20 mL/h.
One group of mice received a single intravenous bolus 10 mg/kg
dose of B20-4.1 24 h prior to measurement. Extracellular volume
measurement was achieved by administering a constant intrave-
nous infusion of
111In pentetate (3700 kBq/mL) at a rate of
300 mL/h for exactly 1 h. Plasma and tissue samples were
collected by retroorbital bleed and terminal organ harvest,
respectively, and counted for radioactivity using a 1480
WIZARD
TM Gamma Counter (Wallac, Turku, Finland) in the
energy window for the 245-keV photon peak of
111In (t1/2=2.8 d)
and with automatic background and decay correction. The
interstitial volume (Vi) was calculated as [(cpmTOTAL of
111In in
1 g tissue) 2 (cpm of
111In in 1 mL of blood)6(Vv)]/(cpm of
111In in
1 mL of plasma).
Volume velocity of organ blood flow
Regional blood flow rates (Q) in various organs and tissues were
determined by sacrificing mice exactly 1 min following IV (caudal)
bolus injection of a 185-kBq quantity of
86RbCl [7,31,35,36,-
37,38]. Tissue samples were promptly collected by terminal organ
harvest and counted for radioactivity using a 1480 WIZARD
TM
Gamma Counter in the energy window for the 1077-keV photon
peak of
86Rb (t1/2=18.7 d) and with automatic background and
decay correction. Blood flow (Q) was calculated as (cpm of
86Rb in
1 g tissue6COtotal)/(cpm of
86Rb in the total injected dose), where
total cardiac output (COtotal)=8000 mL/min for a mouse [4].
SPECT-CT imaging
SPECT-CT imaging of mice with
99mTc-labeled RBCs was
performed as an adjunct to the ex vivo biodistribution studies as
previously described [2]. All mice received a bolus intravenous
dose consisting of
99mTc pertechnetate in 100 mL of saline for the
direct method, or a 200 mL aliquot of
99mTc-labeled whole blood
via the indirect method, with total injected radioactivity in the
range of 10.3-14.4 MBq. Initiation of noninvasive SPECT-CT
imaging was executed 98–138 min from the time of tracer
injection. Image acquisition times for CT and SPECT were an
average of 3 min and 12 min, respectively, with approximately
20,000 counts per projection (20 s per projection) for the latter.
Calculated Vv for all tissues in the imaged mice (data not shown)
agreed well with the data in Table 1. The SPECT and CT data
was transferred to a 2566256 matrix and fused using AMIRAH
graphics software (TGS, San Diego), yielding simultaneous
scintigraphic and anatomic information in all tomographic scans
in the 3 different spatial axes.
PBPK simulations
In order to assess the potential impact of parameter variability on
physiologically-based modeling results, organ level antibody
biodistribution, subsequent to a bolus dose, was simulated using a
previously published PBPK model [13] (Figure 2). The area under
the first seven days of the concentration-time curve (AUC0–7) for
plasma and selected tissues was calculated using parameter values
taken from the literature as well as with the experimentally
measured values (Tables 1, 2, 3) discussed herein. Note that the
literature Vv and Vi values in Tables 1, 2 were derived from
reported fractional blood volumes (c, where c=Vv/Vtissue)a n d
fractional interstitial fluid volumes (w, where w=Vi/Vtissue)b y
assuming a tissue density of 1 g/mL, consistent with assumptions
made in the reference from which they were obtained [5].
Comparisons of AUC0–7 values were made by substituting literature
values of Vv, Vi and Q for liver, kidneys, intestine, spleen and lungs
with experimentally measured (AUC0–7) values [2]. One exception
was made in that the literature value of Vi for kidney was used in all
cases due to renal clearance of
111In-DTPA.
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